Summit Therapeutics (NASDAQ: SMMT)
$23.25
(15.4%)
$3.10
Price as of April 11, 2025, 3:58 p.m. ET
SMMT
Key Data Points
Current Price
$23.25
Daily Change
(15.4%) $3.10
Day's Range
$20.37 - $23.31
Previous Close
$23.24
Open
$20.24
Beta
0.77
Volume
6,650,271
Average Volume
2,737,838
Sector
Market Cap
$17B
Market Cap / Employee
$108M
52wk Range
$2.10 - $33.89
Revenue
-
Gross Margin
0%
Dividend Yield
N/A
EPS
-$0.31
CAPs Rating
-
Industry
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Summit Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Summit Therapeutics Company Info
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
News & Analysis
Featured Article
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Billy Duberstein | Apr 10, 2025
Featured Article
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
Prosper Junior Bakiny | Apr 5, 2025
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
David Jagielski | Apr 3, 2025
Why Summit Therapeutics Stock Slipped Today
Eric Volkman | Mar 26, 2025
Is Summit Therapeutics a Millionaire Maker?
Keith Speights | Mar 23, 2025
This Unstoppable Biotech Stock Just Became an Even Better Buy
Prosper Junior Bakiny | Mar 19, 2025
Why Summit Therapeutics Stock Was Winning This Week
Eric Volkman | Mar 14, 2025
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
David Jagielski | Mar 13, 2025
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.